Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice

Neoplasia

Volumn 8, Issue 7, 2006, Pages 587-595

  Thomas, Carole D ^a,b   Walczak, Christine ^a,b   Kaffy, Julia ^b,c   Pontikis, Renée ^b,c   Jouanneau, Jacqueline ^b,c   Volk, Andreas ^a,b  

^a Centre Universitaire   (France)

^b INSTITUT CURIE   (France)

^c CNRS   (France)

Author keywords

Antivascular therapy; Carbogen; fMRI; Mouse; Rat bladder tumors

Indexed keywords

CARBOGEN; COMBRETASTATIN A4 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER TUMOR; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HISTOPATHOLOGY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR NECROSIS; VASCULARIZATION;

EID: 33745946254     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06232     Document Type: Article

References (30)

1. Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumour blood vessels. Nat Rev 5, 423-435.
2. West CM and Price P (2004). Combretastatin A4 phosphate. Anticancer Drugs 15, 179-187.
3. Beauregard DA, Hill SA, Chaplin DJ, and Brindle KM (2001). The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61, 6811-6815.
4. Hori K, Saito S, and Sato Y (2003). Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs: implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 39, 1957-1966.
5. Stevenson JP, Rosen M, and Sun WJ (2003). Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21, 4428-4438.
6. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, et al. (2005). Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237, 492-499.
7. Bentzen L, Vestergaard-Poulsen P, and Nielsen T (2005). Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys 61, 1208-1215.
8. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, et al. (2002). A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62, 3408-3416.
9. Galbraith SM, Maxwell RJ, and Lodge MA (2003). Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21, 2831-2842.
10. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, and Tozer GM (2002). Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15, 89-98.
11. Zhao D, Jiang L, Hahn WH, and Mason RP (2005). Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62, 872-880.
12. Thomas CD, Chenu E, Walczak C, Plessis MJ, Perin F, and Volk A (2004). Relationship between tumour growth rate and carbogen-based functional MRI for a chemically induced HCC in mice. Magma 17, 271-280.
13. Jouanneau J, Gavrilovic J, Caruelle D, Jaye M, Moens G, Caruelle JP, and Thiery JP (1991). Secreted and non secreted forms of aFGF produced by transfect epithelial cells are active on cell morphology, motility and invasive potential. Proc Natl Acad Sci USA 88, 2893-2898.
14. Jouanneau J, Plouet J, Moens G, and Thiery JP (1997). FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo. Oncogene 14, 671-676.
15. Billottet C, Janji B, Thiery JP, and Jouanneau J (2002). Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2. Oncogene 21, 8128-8139.
16. Lawrence NJ, Ghani FA, Hepworth LA, McGown AT, and Pritchard RG (1999). The synthesis of (E) and (Z)-combretastatins A-4 and phenanthrene from Combretum caffrum. Synthesis 9, 1656-1660.
17. Pettit GR and Rhodes MR (1998). Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anti-Cancer Drug Des 13, 183-191.
18. Cohen-Solal C, Parquet M, Tiffon B, Volk A, Laurent M, and Lutton C (1995). Magnetic resonance imaging for the visualization of cholesterol gallstones in hamster fed a new high sucrose lithogenic diet. J Hepatol 22, 486-494.
19. Thomas CD, Chenu E, Walczak C, Plessis MJ, Perin F, and Volk A (2003). Morphological and carbogen-based functional MRI of a chemically induced liver tumor in mice. Magn Reson Med 50, 522-540.
20. Yamamoto A, Dhar DK, El-Assal ON, Igarashi M, Tabara H, and Nagasue N (1998). Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol 29, 290-299.
21. Ahmed B, Van Eijk LI, Bouma-ter Steege JCA, Van der Schaft DWJ, Van Esch A, Joosten-Achjanie SR, Lambin P, Landuyt W, and Griffioen AW (2003). Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 105, 20-25.
22. Chaplin DJ and Hill SA (2002). The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54, 1491-1496.
23. Anderson HL, Yap JT, Miller M, Robbins A, Jones T, and Price PM (2003). Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin phosphate. J Clin Oncol 21, 2823-2830.
24. Rustin GJS, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, and Price PM (2003). Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21, 2815-2822.
25. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford M, Dennis MF, and Chaplin DJ (1999). Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59, 1626-1634.
26. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, and Chaplin DJ (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61, 6413-6422.
27. Zhao D, Jiang L, Hahn WH, and Mason RP (2005). Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62, 872-880.
28. Hori K, Saito S, and Kubota K (2002). A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86, 1604-1614.
29. Robinson SP, Rodrigues LM, Ojugo AS, McSheehy PM, Howe FA, and Griffiths JR (1997). The response to carbogen breathing in experimental tumor models monitored by gradient-recalled echo magnetic resonance imaging. Br J Cancer 75, 1000-1006.
30. Furman-Haran E, Margalit R, Grobgeld D, and Degani H (1996). Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. PNAS 93, 6247-6251.